Fasciola hepatica hijacks host macrophage miRNA machinery to modulate early innate immune responses

Nham Tran1,5, Alison Ricafrente2,5, Joyce To2, Maria Lund2, Tania M. Marques3, Margarida Gama-Carvalho3, Krystyna Cwiklinski4, John P. Dalton4 & Sheila Donnelly2* 

Fasciola hepatica, a global worm parasite of humans and their livestock, regulates host innate immune responses within hours of infection. Host macrophages, essential to the first-line defence mechanisms, are quickly restricted in their ability to initiate a classic protective pro-inflammatory immune response. We found that macrophages from infected animals are enriched with parasite-derived micro(mi)RNAs. The most abundant of these miRNAs, fhe-miR-125b, is released by the parasite via exosomes and is homologous to a mammalian miRNA, hsa-miR-125b, that is known to regulate the activation of pro-inflammatory M1 macrophages. We show that the parasite fhe-miR-125b loads onto the mammalian Argonaut protein (Ago-2) within macrophages during infection and, therefore, propose that it mimics host miR-125b to negatively regulate the production of inflammatory cytokines. The hijacking of the miRNA machinery controlling innate cell function could be a fundamental mechanism by which worm parasites disarm the early immune responses of their host to ensure successful infection.

Helminths, or worms, are multicellular parasites that can live for many years within their vertebrate hosts. Of prime importance is the regulation of the host immune cell signalling pathways to prevent the parasite's elimination before they can produce their off-spring in the form of eggs. Many worm parasites inactivate innate cell detection systems, such as macrophage and dendritic inflammatory responses, and direct the adaptive immune response towards a tolerant or hyporesponsive state1–4. Understanding how worm parasites do this will inform the design of new anti-helminthic treatments, such as drugs or vaccines.

Fasciola hepatica, or liver fluke, is a global zoonotic food-borne parasite that infects humans and their livestock. The parasite is one of the most successful helminths as it is found on every inhabited continent and infects the widest variety of mammalian hosts infected by any worm, including some that it has encountered only in relatively recent times (e.g. camels and marsupials)5,6. This implies a superior adaptation to the mammalian host and suggests that F. hepatica parasites have evolved a universal process of invasion, tissue migration and immune modulation.

Mammalian hosts become infected with F. hepatica following ingestion of vegetation contaminated with encysted parasites (metacercariae). Within the intestine, juvenile parasites emerge from their cysts (termed newly excysted juveniles, NEJ) and within ~ 2 to 6 h traverse the intestinal wall and enter the peritoneal cavity. During the next 2–3 days of infection they rely on stored glycogen resources to migrate from the peritoneal cavity into the liver parenchyma where they begin to rapidly grow and develop. Their migratory activity in the liver causes the extensive haemorrhaging and tissue destruction associated with acute disease. During the invasion and pre-hepatic migratory stage, animals display no clinical signs of infection, and, histologically, no significant inflammatory changes are observed in the intestinal wall or peritoneal cavity7,8. This suggested that the parasites employ a mechanism(s) to disarm the host’s innate ‘early-response’ immune system to prevent their detection at a vulnerable time in their invasion.

1School of Biomedical Engineering, Faculty of Engineering and Information Technology, The University of Technology Sydney, Ultimo, NSW, Australia. 2School of Life Sciences, Faculty of Science, The University of Technology Sydney, Ultimo, NSW, Australia. 3BiosISI–Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal. 4Center of One Health (COH) and Ryan Institute, School of Natural Science, National University of Ireland Galway, Galway, Ireland. 5These authors contributed equally: Nham Tran and Alison Ricafrente. *email: Sheila.Donnelly@uts.edu.au
Within the peritoneal cavity macrophages are the primary immune cell contributing to the immediate response to invading pathogens and are the predominant innate immune cell present during the first days of infection with *F. hepatica*. Macrophages are major regulators of the inflammatory response as they monitor blood and tissues for signs of infection or damage and alert adaptive immune cells to any incursions. In response to invading pathogens, macrophages are typically ‘classically activated’ by signals from the pathogen itself and from damaged host tissue. This ‘M1’ phenotype of macrophage displays enhanced phagocytic and antigen presentation capacity and drives host protective immune responses by producing pro-inflammatory cytokines (such as TNF, IL-6 and IL-12) and anti-microbial effector molecules (like nitric oxide; NO). Despite the presence of migrating *F. hepatica* parasites, the levels of NO produced by peritoneal macrophages isolated from infected sheep are the same as macrophages from uninfected sheep. Furthermore, peritoneal macrophages from infected sheep show no significant increase in the expression levels of pro-inflammatory cytokines (TNF, IL-12, IFNγ, iNOS). Importantly, this modulation of pro-inflammatory immune responses is also evident in experimental infections in mice. The absence of a classical host protective inflammatory response to invading *F. hepatica* implies that the parasite possesses an effective mechanism of control on macrophage activity.

Helminth parasites secrete a range of soluble proteins/glycans that have been shown to suppress the ability of host macrophages to differentiate to M1 phenotype. More recently, a role for miRNAs in the regulation of host immune responses by parasitic worms has been suggested. Comparative analysis of parasite genomes has shown that some helminth miRNAs are widely conserved while others are specific to particular helminths. Moreover, a number of the conserved miRNAs share sequence identity with mammalian miRNAs that are known to have an immune regulatory function. Target prediction software suggests that helminth miRNAs may act to regulate host immune responses to enable their development and survival. However, to date, the evidence to support this proposed miRNA-mediated mechanism of immune modulation has come from in vitro analysis of transfected cells or the identification of parasite miRNAs in sera or tissue of infected hosts. Here we show that *F. hepatica* releases miRNAs, that are homologous to host miRNAs, that regulate macrophage function in vivo and propose that worms may hijack this process to control their host's early immune responses.

### Results

**Parasite-derived miRNAs are located within macrophages during infection with *Fasciola hepatica***. To investigate whether miRNAs produced by *F. hepatica* contributed to the inhibition of macrophage activation in early infection, we orally infected BALB/c mice with *F. hepatica* metacercariae and searched for parasite miRNAs in peritoneal macrophages at selected time-points (6 h, 12 h, 24 h, 3 days and 5 days after infection) using RNASeq (deposited in NCBI’s GeneExpression Omnibus; accession number GSE145597; [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145597](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145597)). After first cleaning the datasets obtained, reads were mapped against the mouse database from miRBase (mmu). Then, to identify *F. hepatica*-specific miRNAs the remaining 15,796,193 reads were screened against the miRBase list of 30 *F. hepatica* miRNAs. Using this approach, we identified 10 *F. hepatica* miRNAs that were present within peritoneal macrophages of infected mice (Table 1). *F. hepatica* mir-125b (fhe-miR-125b) was the most abundant miRNA observed in peritoneal macrophages during the first 24 h of infection, with expression peaking at approximately 12 h after infection. This is coincident with the migration of NEJs through the intestine and into the peritoneal cavity, and with the observed early suppression of host innate immune responses, as described above. Using RT-qPCR (Fig. 1a). Consistent with these observations, the expression of *fhe-miR-125b* was also observed in peritoneal cells isolated from sheep after an experimental infection with 150 metacercariae (Fig. 1b). These miRNAs were not detected in peritoneal macrophages taken from non-infected mice or sheep (Fig. 1a,b).

| *Fasciola* miR    | Time after infection | Uninfected | 6 h  | 12 h  | 24 h  | 3 days | 5 days |
|-------------------|----------------------|------------|------|-------|-------|--------|--------|
| fhe-bantam        | -                    | -2         | 1    | -     | -     | -      | -      |
| fhe-miR-125b      | -                    | -1         | 16   | 6     | 18    | 1      | 2      |
| fhe-miR-36a       | -                    | -1         | 12   | -     | -     | -      | -      |
| fhe-miR-61        | -                    | -3         | 5    | 3     | -     | -      | -      |
| fhe-miR-125a      | -                    | -1         | 1    | -     | -     | -      | -      |
| fhe-miR-46        | -                    | -1         | 1    | -     | -     | -      | -      |
| fhe-miR-277       | -                    | -2         | -    | -     | -     | -      | -      |
| fhe-miR-10        | -                    | -1         | -    | -     | -     | -      | -      |
| fhe-miR-219       | -                    | -1         | -    | -     | -     | -      | -      |
| fhe-miR-71b       | -                    | -1         | -    | -     | -     | -      | -      |

Table 1. Read numbers of known *Fasciola hepatica* miRNAs detected by miRNASeq in peritoneal macrophages harvested from infected mice over a time-course of 5 days. Two biological samples were sequenced at each time point with read counts for each sample presented in columns below. “–” no read counts detected.
which for Supporting the miRDB initial analysis, TRAF6 was one of only 43 genes that were commonly predicted as targets two additional predictive tools were then used, miRanda and TargetScan (Supplementary Table 1). miR-125b, events were over-represented (Fig. 2e). To further scrutinise if Traf6 could be the prime target candidate for only two gene targets emerged; Traf6 and Nlrc5. Pathway analysis of the interactions showed that Traf6-mediated filtered down to cell specific associations restricted to peritoneal macrophages. Surprisingly, from this analysis, it is most abundant (Fig. 2f), fhe-miR-125b toneal macrophages harvested from mice at the same timepoints that immune-related protein–protein interactions with an enrichment in the nucleus (Fig. 2c). This dataset was then provides experimental evidence to validate the predictive analysis. As a transcription factor that is central to study, EVs were harvested from in vitro cultured NEJs and shown to contain fhe-miR-125b (Fig. 1d). Previous studies have documented human miR-125b expression, supporting the idea that worm miRNAs govern developmental processes. In the context of a role in fhe-miR-125b was most abundant in NEJs, the stage that initiate infection. miR-125b fhe- expression, demonstrating that the expression of a miR-125b is specific to trematode parasites. Comparison of the expression of fhe-miR-125b across the different intra-mammalian life-stages of F. hepatica revealed strict temporal expression, supporting the idea that worm miRNAs govern developmental processes. In the context of a role in the immune modulation of innate immune responses after infection, it was notable that the expression of fhe-miR-125b was most abundant in NEJs, the stage that initiate infection.

Several studies suggest that extracellular vesicles (EVs) are the main reservoir of exogenous miRNAs. In this study, EVs were harvested from in vitro cultured NEJs and shown to contain fhe-miR-125b (Fig. 1d). Since EVs released during helminth infections are primarily taken up by macrophages this provides a mechanism by which fhe-miR-125b and other miRNAs are delivered into the macrophages.

**Fasciola hepatica miR-125b targets innate immune signalling pathways.** The secondary structure of fhe-miR-125b indicates a typical miRNA with the mature strand located on the 5′ arm of the precursor (Fig. 2a). Previous studies have documented human hsa-miR-125b as a miRNA that regulates the inflammatory response of macrophages by controlling the activation of M1 macrophages. Using a phylogenetic approach, we compared the structure of fhe-miR-125b to its human homologue and to miR-125 sequences from the closely related trematodes, Schistosoma mansoni and Caenorhabditis elegans. (d) RT-qPCR using primers specific for fhe-miR125b was carried out on RNA extracted from NEJ extracellular vesicles (EVs). In these experiments, levels of fhe-miR125b expression determined by RT-qPCR are represented as the starting quantity of genetic material prior to amplification (N0) as determined by LinRegPCR (v.11). The data is presented as the mean ± SD of triplicate biological samples.

RT-qPCR. This confirmed that fhe-miR-125b is expressed by the NEJ parasites (Fig. 1c). RT-qPCR also demonstrated that miR-125b could be amplified from RNA isolated from Schistosoma mansoni, a trematode parasite like F. hepatica, but not from the free-living nematode Caenorhabditis elegans. This result concurs with reports demonstrating that the expression of a miR-125b is specific to trematode parasites. Comparison of the expression of fhe-miR-125b across the different intra-mammalian life-stages of F. hepatica revealed strict temporal expression, supporting the idea that worm miRNAs govern developmental processes. In the context of a role in the immune modulation of innate immune responses after infection, it was notable that the expression of fhe-miR-125b was most abundant in NEJs, the stage that initiate infection.

Several studies suggest that extracellular vesicles (EVs) are the main reservoir of exogenous miRNAs. In this study, EVs were harvested from in vitro cultured NEJs and shown to contain fhe-miR-125b (Fig. 1d). Since EVs released during helminth infections are primarily taken up by macrophages this provides a mechanism by which fhe-miR-125b and other miRNAs are delivered into the macrophages.

**Fasciola hepatica miR-125b targets innate immune signalling pathways.** The secondary structure of fhe-miR-125b indicates a typical miRNA with the mature strand located on the 5′ arm of the precursor (Fig. 2a). Previous studies have documented human hsa-miR-125b as a miRNA that regulates the inflammatory response of macrophages by controlling the activation of M1 macrophages. Using a phylogenetic approach, we compared the structure of fhe-miR-125b to its human homologue and to miR-125 sequences from the closely related trematodes, Schistosoma mansoni and Caenorhabditis elegans. (d) RT-qPCR using primers specific for fhe-miR125b was carried out on RNA extracted from NEJ extracellular vesicles (EVs). In these experiments, levels of fhe-miR125b expression determined by RT-qPCR are represented as the starting quantity of genetic material prior to amplification (N0) as determined by LinRegPCR (v.11). The data is presented as the mean ± SD of triplicate biological samples.
The hairpin structure of fhe-miR125b, produced by RNAfold, was identified using GO tool DAVID. The expression of TRAF6 was measured in RNA extracted from peritoneal macrophages harvest peritoneal macrophages harvested from infected (Uninf) or control (Uninf) infected mice at 6 h and 12 h after an oral infection with F. hepatica. The level of expression is represented as the starting quantity of genetic material prior to amplification (N0) as determined by LinRegPCR (x:11). The data is representative of three independent experiments and is presented as the mean ± SD of triplicate biological samples. The data was analyzed using one-way analysis of variance (ANOVA).

To provide experimental proof of the ability of fhe-miR-125b to directly engage in the regulation of pro-inflammatory pathways in macrophages, primary murine macrophages were transfected with synthetic versions of both the F. hepatica and human miR-125b. While neither miRNA had any apparent effect on macrophages when transfected under basal culturing conditions, both transfactions significantly inhibited the ability of macrophages to express TRAF6 in response to a challenge with bacterial LPS (Fig. 3a) and, as a consequence, the production of both IL-6 and TNF were significantly reduced (Fig. 3b,c). This outcome was specific to the miR-125b transfection with a scrambled non-targeting miRNA had no effect. We propose, therefore, that the F. hepatica fhe-miR-125b, like its mammalian counterpart, functions to regulate the ability of macrophages to respond to pro-inflammatory signalling, thus preventing the differentiation to an M1 phenotype.

Fasciola hepatica miR-125b complexes with the mammalian Argonaute-2 protein in host macrophages to regulate mammalian gene expression. The mechanism(s) by which the exogenous worm miRNAs operate in mammalian immune cells to alter their function remains enigmatic. However, studies in mammalian cells have shown that in the first step miRNAs must form a complex with an Argonaute protein (Ago). This Ago-miRNA association forms the core of the miRNA-induced silencing complex (miRISC), which is then guided by the complexed miRNA to bind complementary (target) sequences in the messenger RNA (mRNA). Helminth Ago proteins have been detected within secreted EVs and may be involved in the regulation of mammalian target genes. However, given the similarity of fhe-miR-125b to its mammalian homolog we surmised that helminth miRNAs delivered into immune cells could directly load onto mammalian Ago2. In this way worm miRNAs would compete with the mammalian miRNA machinery to influence host gene expression. To test this idea, murine Ago2 was isolated by immunoprecipitation from the peritoneal macrophages taken at 6 h and 12 h post infection (IP; Supplementary Fig. 2) and the miRNA extracted and subjected to RT-qPCR. We used the detection of murine miR-21 as a control for the pulldown and to demonstrate the normalisation of input miRNA to the RT-qPCR. This miRNA has been characterised as a central regulator of macrophage activity and its expression is enhanced by inflammatory stimuli. Therefore, the observation of this murine miRNA loaded onto the Ago-2 within peritoneal macrophages of infected mice at both 6 h and 12 h, but not in uninfected animals (Fig. 3d) supports the efficacy of the pulldowns and validates the normalisation of miRNA input to the RT-qPCR. In contrast, the parasite-derived mir-125 was loaded onto Ago-2 only at 12 h timepoint (a time when fhe-miR-125b expression was at its peak; Table 1) reflecting the changes to the loading of mir-125b as a result of the progression of parasite infection (Fig. 3d).
Several parasitic worm miRNAs share homology with mammalian miRNAs. Thus, they have the capacity to regulate the expression of an array of host genes within macrophages and other innate cells to effectively evade expulsion and continue their growth and development to maturity. Our gene target analysis and in vitro studies pinpoint a specific mechanism whereby F. hepatica could interrupt the MAPK signalling pathway of innate immune responses via the regulation of TRAF6 by fhe-miR-125b. This mechanism is supported by the presence of a single miR-125b binding site on the 3′ UTR of TRAF6. The identification of mammalian genes and immune pathways targeted by parasite miRNAs has major implications for our understanding of the interaction between parasite and host.

It is highly significant that miR-125b, the most predominant parasite miRNA found in host macrophages of mice infected with F. hepatica, is conserved amongst the trematode clade of helminths, including the blood flukes of the genus Schistosoma, as it points towards a common mechanism for the anti-inflammatory control amongst these important parasites of humans and their livestock. Indeed, recent studies have shown that the miR-125b orthologues are highly enriched in EVs released by S. mansoni and S. japonicum, representing 40% and 65% respectively of the total miRNA reads. However, in contrast to the immune modulatory effect of fhe-miR-125b we have shown here, transcription of murine macrophages with sja-miR-125b resulted in the induction of pro-inflammatory immune responses as assessed by an increased production of TNF. Predictive analysis of this parasite miRNA led Liu et al. to suggest that the sja-miR-125b was targeting the expression of Pros1, a gene known to inhibit TLR-driven pro-inflammatory responses. Neither of the three predictive tools used in our study, predicted this gene as a target for the F. hepatica miR-125b, nor was it identified amongst the genes downregulated in macrophages isolated from infected mice. These contrasting observations could suggest that miR-125b plays different functions for different parasites. Unlike F. hepatica, a pro-inflammatory Th1-type immune response dominates during the first 3–5 weeks of infection with Schistosome parasites. As the parasites mature and females become fecund, parasite eggs trapped in tissues induce potent Th2 responses that suppress Th1 responses. The sja-miR-125b was identified within EVs isolated from parasites collected from mice at 28 days post-infection, a pre-patent time point, coincident with a strong Th1 pro-inflammatory immune response.

A single miRNA can influence the expression of a multitude of different genes. mRNA silencing efficiency is determined by the sequence of the seed region, free energy produced by the miRNA-target duplex and stability of the miRNA 5′ terminal and seed region. While high specificity of the miRNA seed sequence has been largely reported as the crucial factor to miRNA target recognition, nucleotide pairings outside of the seed are also known to affect gene target recognition and overall thermodynamic stability of the miRNA-targetduplex. These key concepts are integrated in predictive tools such as miRDB and MiRanda that scrutinise whole mature miRNA sequences. Examining the overall structure of miR-125 from various species, phylogenetic analysis indicates that fhe-miR-125b is closely related to its human counterpart and distal to that of miR-125b found in Schistosoma. This may explain why Pros1 was not predicted to be a target for fhe-miR-125b and only regulated by sja-miR-125b. It would be interesting to determine which exact nucleotides outside the seed region may account for this specificity.

miRNAs are not functional until they are loaded onto an Ago protein, a process that facilitates base-pairing to mRNA targets and ultimately translational repression and mRNA degradation. Here we provide proof that exogenous, worm-derived miRNA is delivered into macrophages, probably via exosomes, during infection and loads onto host Ago2. Coupled with our in vitro transfection studies that shows fhe-miR-125b can alter macrophage phenotype we can deduce that parasite miRNAs are functional within mammalian cells. We have to assume that this binding mimics that of host hsa-miR-125b and, therefore, operates in the same way, to regulate the pro-inflammatory response of macrophages.

It has been reported that miRNAs that have homologs in mammalian hosts dominate the miRNA cargo of F. hepatica EVs. However, a number of miRNAs which are novel to the parasite have also been identified here and elsewhere. Predictive analysis suggests that these too have the capacity to regulate immune-related mammalian genes. As the loading of miRNAs to Ago protein is a very precise process with the requisite thermodynamics and base-match composition, it remains to be determined whether homology to a mammalian miRNA is essential for a parasite miRNA to associate with mammalian Ago and hence the mammalian miRNA machinery.

The ability of F. hepatica to invade, infect and produce progeny in a very broad range of species indicates a strong universal compatibility between the parasite and its mammalian host, particularly in terms of attuning the immune response. This study provides direct in vitro and in vivo evidence for the role of helminth-derived
miRNAs in this complex parasite-host immune-interplay. Further elucidation of how mechanisms of immune modulation, involving nucleic acids, proteins and glycans, are employed by the parasite, especially during the early stage of infection, is critical for development of effective anti-helminth therapies to prevent infection and pathogenesis.

**Methods**

**Murine and sheep infections.** Six to eight week old female BALB/c mice (Australian Resource Centre, Perth, Australia) were orally infected with 20 metacercariae of *F. hepatica* (Baldwin Aquatics Inc, USA). Peritoneal exudate cells were collected by washing the peritoneal cavity with 5 ml of sterile saline. Ethical approval for this study was granted by the University of Technology Sydney (UTS) Animal Care and Ethics Committee (Approval Number: 2012-080) and experiments were conducted in accordance with the approved guidelines to be compliant with The Australian Code for the Care and Use of Animals for Scientific Purposes.

Ten 6 month-old male Dorset cross sheep (UK) were orally infected with 150 *F. hepatica* metacercariae (South Gloucester isolate, Ridgeway Research Ltd) administered in water. Animals were euthanized at selected time points post infection by captive bolt and peritoneal cells harvested as previously described. These experimental procedures were reviewed and approved by the Agri-Food Biosciences Institute (AFBI) Animal Ethics Committee, Northern Ireland, UK and carried out in accordance with the conditions of the operating license issued from the Department of Health, Social Services and Public UK by the Animal (Scientific Procedures) Act 1986 (License No. PPL 27771). All animal work was performed and reported according to the ARRIVE guidelines.

**Preparation of murine macrophages.** Peritoneal macrophages were separated from the complete exudate cell population by negative selection using magnetic beads in accordance with the manufacturer's instructions (Miltenyi, USA). Bone marrow cells isolated from BALB/c mice were differentiated for 6 days in RPMI 1640 supplemented with FBS (10%v/v) and recombinant M-CSF (50 ng/ml; eBioscience, San Diego, CA, USA).

**Small RNA library preparation and bioinformatics analysis.** The quality of the raw fastq files was assessed using FastQC and the adapters were removed using Cutadapt v1.13. The sequences with length smaller than 18 bp were discarded also using Cutadapt. The reads were then pre-processed with an in-house perl script that filters homopolymers, sequences that contain Ns and low quality reads. The mature miRNA sequences of *Mus musculus* were retrieved from miRbase and used to build the index for the alignment using bowtie. After the pre-processing, the reads were aligned against the mouse mature miRNAs. The reads that did not align against the mouse mature miRNAs were aligned against the *F. hepatica* known miRNAs. After the alignments, another in-house script was used to count the reads that were successfully mapped.

**Preparation of parasite RNA.** *Fasciola hepatica* metacercariae were sourced from Ridgeway Research Ltd, UK. The South Gloucester isolate was used to infect sheep which allowed the recovery of adult worms from the bile ducts. BALB/c mice aged 6–8 weeks were orally infected with 30 metacercariae of *F. hepatica* (Italian isolate, Ridgeway Research Ltd) to recover the 21 day old immature flukes. All animal experimental procedures were carried out at Queen's University Belfast, UK under license from the Home Office by the Animal (Scientific Procedures) Act 1986 (License No. PPL/2806) after ethical review by the Queen's University Belfast Animal Welfare and Ethical Review Body. The Italian isolate was also used for the excystment of newly excysted juveniles (NEJ) and parasite culture for the recovery of extracellular vesicles (EVs). Total RNA from all parasitic stages (NEJ, NEJ EV, immature and adult worms) was extracted using the miRNeasy Mini Kit (Qiagen) according to the manufacturer's instructions, eluted in 30 μl RNase-free water.

**Caenorhabditis elegans** were maintained in 35 mm diameter petri dishes containing Nematode Growth Medium agar, (3 g NaCl, 17 g agar, 2.5 g peptone, 1 ml 1 M CaCl₂, 1 ml 5 mg/mL cholesterol in ethanol, 1 ml 1 M MgSO₄, 25 ml 1 M KPO₄ buffer [pH 6.0, 108.3 g KH₂PO₄, 35.6 g K₂HPO₄, H₂O to 1 L]) seeded with a lawn of *Escherichia coli* OP50. After 3–4 days, when all life stages of worms were present (embryo, larvae stages 1–4, and adult), worms were sub-cultured into new plates containing NGM agar and *E. coli* OP50. Once adequate numbers were achieved, worms were harvested by washing petri dishes with S buffer (129 ml 0.05 M KH₂PO₄, 871 ml 0.05 M KH₂PO₄, and 5.85 g NaCl), and scraped off agar with a sterile glass rod. The worm suspension was then centrifuged at 1000×g for 5 min, and the pellet containing the worms washed with sterile PBS. The final worm pellet was resuspended in 1 ml RNAzol RT (Molecular Research Centre Inc, USA) and homogenised with mortar and pestle for RNA extraction.

Adult males and female *S. mansoni* worms (n = 166) in RNAlater stabilisation solution (Life Technologies, USA) was kindly donated by Prof. Donald McManus (Queensland Institute of Medical Research). Worms were washed with sterile PBS to remove RNAlater by centrifugation at 1000×g for 5 min at 4 °C. The final worm pellet was resuspended in 2 ml of RNAzol RT and homogenised with mortar and pestle for RNA extraction.

**Preparation of macrophage extracellular vesicles.** RAW 264.7 macrophages were cultured to confluency in RPMI + 10% FBS (v/v) at 37 °C and 5% CO₂. Cells were collected by scraping and cellular debris removed by sequential centrifugation steps of 2000×g for 20 min at 4 °C followed by 10,000×g for 30 min at 4 °C. To obtain the extracellular vesicles the supernatant was subjected to ultracentrifugation at 104,492×g for 2 h at 4 °C and the pellet material re-suspended to maximum volume depending on the size of the centrifuge tube. This resuspension was then ultracentrifuged at 104,492×g overnight at 4 °C to separate the soluble proteins (now in the supernatant) and vesicles (now in the pellet).
miRNA target prediction. To determine possible gene targets of selected *F. hepatica* miRNA, the miRNA sequence of *fhe-miR-125b* was initially analysed using custom prediction with a murine background on the online miRNA target prediction tool, miRDB (mirdb.org). Additionally, mouse mRNA 3′UTR sequences were analysed for *fhe-miR-125b* target pairing using miRNA target predictive tools miRanda (http://www.microrna.org/) and TargetScan (http://www.targetscan.org). miRNA:mRNA pairings with a target score of > 60 were considered in miRanda, and a seed sequence match of 7mer-m8 site in TargetScan. Only common genes determined by all predictive tools were considered for further analysis. The acquired list of gene targets was analysed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 (david.ncifcrf.gov) and significant pathways targeted by *fhe-miR-125a* were determined using the murine Kyoto Encyclopaedia of Genes and Genomes (KEGG) database.

Microarray analysis. Microarray analyses were performed using the Illumina whole genome microarray platform (Illumina, USA) as previously described. Quality control of data was performed using GenomeStudio (version 1.1.1, Illumina) by examining intensity histograms of hybridisation efficiency and noise. GeneSpring GX version 11 (Agilent Technologies, Foster City, USA) was used for all subsequent data analyses. All data were entered into GeneSpring GX 11 and normalised to the 75th percentile. Data for each replicate were normalised to respective uninfected controls and filtered for significance on the basis of detection score, a GenomeStudio generated measure of signal intensity relative to background. At least half of all hybridisations had to have a detection score > 0.949, (which equates to a confidence value of p ≤ 0.05) for a gene to be accepted. Gene expression values for commonly up- and down-regulated genes were averaged and a Students t-test was performed to identify significant changes in gene expression compared with controls (p ≤ 0.05). An additional cut-off of ± two-fold change in expression was applied to identify changes in gene expression with likely biological significance.

Transfection of bone marrow derived murine macrophages. Bone marrow derived macrophages (1 × 10^6 cells/500 µl) were transfected with synthetic miRNAs (20 nM; (IDT, USA) combined with Lipofectamine RNAiMAX (Life Technologies, USA) over a period of 24 h in accordance to manufacturer's protocol. Transfected cells were washed with sterile PBS before stimulation with *E. coli* lipopolysaccharide (LPS; 10 ng/ml) for 6 h at 37 °C and 5% CO₂ to induce an inflammatory response. Non-transfected cells, and cells treated with Lipofectamine RNAiMAX alone, without LPS stimulation, were also analysed to control for contamination and possible immune responses induced by transfection reagents. Non-transfected cells were stimulated with LPS to determine the baseline inflammatory response of cultured macrophages. After LPS stimulation, the culture media was collected from all treatment groups for cytokine assays, and the cells washed with sterile PBS and collected for RNA extraction.

RNA extraction from mammalian cells. Cells or extracellular vesicles were homogenised with the RNAzol RT at 1 mL to 10^7 cells. Ultrapure DNase/RNase free distilled water (dH₂O) (Life Technologies, USA) was added to the homogenate, at 0.4 mL of dH₂O per 1 mL of RNAzol RT used, and then centrifuged at 12,000×g for 15 min at 4 °C, to pellet DNA, proteins, and polysaccharides. Supernatant containing soluble RNA was collected and combined with 4-bromoanisole (BAN; Sigma-Aldrich, USA) at 0.5% of supernatant volume, and then centrifuged at 12,000×g for 10 min at 4 °C to pellet residual DNA, proteins, and polysaccharides. To precipitate RNA, the supernatant was collected and combined with isopropanol (100% v/v; Sigma-Aldrich, USA) and 5 μL glycogen (5 mg/mL; Life Technologies, USA), and incubated overnight at − 20 °C. The RNA precipitate was pelleted by centrifugation at 12,000×g for 10 min at 4 °C, washed with 500 μL ethanol (75% v/v; Sigma-Aldrich, USA) twice and re-solubilised in 25 μL dH₂O. Concentrations and quality of isolated RNA was measured using the NanoDrop One/One UV–Vis spectrophotometer (Life Technologies).

Pull-down of argonaute-2 (Ago-2)-bound miRNA from peritoneal macrophages. Peritoneal macrophages were collected and pooled from five uninfected or infected mice for Ago2 pulldown using the MagCapture microRNA isolation kit specific for mouse Ago-2 (FUJIFILM Wako Pure Chemical, JPN) according to manufacturer's instructions. Briefly, cleared cell lysate from each pooled sample of 2 × 10^6 macrophages was incubated with AntiMouse Ago2 magnetic beads for 2 h at 4 °C with rotation. The beads were then washed and subjected to Proteinase K digestion. RNA was isolated from the digest using RNAzol RT and quantified using Qubit Fluorometer with a microRNA Assay kit (ThermoFisher Scientific). The miRNA samples were then normalised to a concentration of 0.5 ng/sample for RT-qPCR. This two-step normalisation of cell number and input miRNA ensured that all samples contained similar amounts of miRNA for comparable analysis by RT-qPCR.

RT-qPCR. After extraction of RNA, all samples were normalised to 100 ng/µl prior to cDNA synthesis. cDNA synthesis was carried out using the TaqMan MicroRNA Reverse Transcription Kit (Life Technologies, USA) according to manufacturer's instructions. Synthesised cDNA was further diluted 1:4 dH₂O. For RT-qPCR, 1 µL of diluted cDNA was combined with 5 µL of SensiFAST Probe Hi-ROX Kit (Bioline, UK), 3.5 µL dH₂O, and 0.5 µL of TaqMan Probe for gene expression or miRNA. Samples were prepared on a MicroAmp optical 96-well reaction plate as technical triplicates (Life Technologies, USA) and analysed using the QuantStudio 6 flex real-time PCR system (Life Technologies, USA). Data was analysed using LinRegPCR v2017.1, and presented as absolute expression of genetic material prior to amplification (N0). The N0 value is the raw fluorescent value and an indication of the expression.
Cytokine assay. The quantities of IL-6 and TNF secreted by transfected bone marrow derived macrophages was determined using ELISA kits (BD Biosciences, USA) according to manufacturer's instructions.

Statistical analysis. Results were analysed using Graphpad prism software (version 8). Comparisons between samples were made using one-way ANOVA with Tukey post hoc test. Differences were considered significant when *P* ≤ 0.05.

Received: 3 April 2020; Accepted: 8 March 2021
Published online: 24 March 2021

References
1. Maizels, R. M. et al. Helminth parasites–masters of regulation. *Immunol. Rev.* 201, 89–116 (2004).
2. Maizels, R. M. & McSorley, H. J. Regulation of the host immune system by helminth parasites. *J. Allergy Clin. Immunol.* 138, 666–675 (2016).
3. Motran, C. C. et al. Helminth infections: Recognition and modulation of the immune response by innate immune cells. *Front. Immunol.* 9, 664 (2018).
4. Johnston, C. J., McSorley, H. J., Anderton, S. M., Wigmore, S. J. & Maizels, R. M. Helminths and immunological tolerance. *Transplantation* 97, 127–132 (2014).
5. Garcia, H. H., Moro, P. L. & Schantz, P. M. Zoonotic helminth infections of humans: Echinococcosis, cystercercosis and fascioliasis. *Curr. Opin. Infect. Dis.* 20, 489–494 (2007).
6. Mas-Coma, S., Bargues, M. D. & Valero, M. A. Fascioliasis and other plant-borne trematode zoonoses. *Int. J. Parasitol.* 35, 1255–1278 (2005).
7. Kelly, W. The liver and biliary system. In *Pathology of Domestic Animals* (eds Jubb, K. E. et al.) 319–406 ( Academic Press, 1993).
8. Kendall, S. & Parfitt, J. The chemotherapy of fascioliasis. *Br. Vet. J.* 118, 1–10 (1962).
9. Mooney, J. E. et al. Transcriptional switching in macrophages associated with the peritoneal foreign body response. *Immunol. Cell Biol.* 92, 518–526 (2014).
10. Ruiz-Campillo, M. T. et al. Study of peritoneal macrophage immunophenotype in sheep experimentally infected with *Fasciola hepatica*. *Vet. Parasitol.* 257, 34–39 (2018).
11. Pérez-Caballero, R. et al. Comparative dynamics of peritoneal cell immunophenotypes in sheep during early and late stages of the infection with *Fasciola hepatica* by flow cytometric analysis. *Parasit. Vectors.* 11, 640 (2018).
12. Murray, P. J. & Wynn, T. A. Protective and pathogenic function of macrophage subsets. *Curr. Opin. Infect. Dis.* 31, 85–95 (2017).
13. Pérez-Caballero, R. et al. Expression of free radicals by peritoneal cell of sheep during the early stages of *Fasciola hepatica* infection. *Parasit. Vectors.* 11, 500 (2018).
14. Ruiz-Campillo, M. T. et al. Immune signatures of pathogenesis in the peritoneal compartment during early infection of sheep with *Fasciola hepatica*. *Sci. Rep.* 7, 27827 (2017).
15. O’Neill, S. M. et al. *Fasciola hepatica* infection downregulates Th1 responses in mice. *Parasite Immunol.* 22, 147–155 (2000).
16. Donnelly, S. et al. Helminth cytokine proteases inhibit TRIF-dependent activation of macrophages via degradation of TLR3. *J. Biol. Chem.* 285, 3383–3392 (2010).
17. Dowling, D. J. et al. Major secretory antigens of the helminth *Fasciola hepatica* activate a suppressive dendritic cell phenotype that attenuates Th17 cells but fails to activate Th2 responses. *Infect. Immun.* 78, 793–801 (2010).
18. Alvarado, R. et al. The immune modulatory peptide FhHDM-1 secreted by the helminth *Fasciola hepatica* prevents NLPR3 inflammasome activation by inhibiting endolysosomal acidification in macrophages. *FASEB J.* 31, 85–95 (2017).
19. Robinson, M. W. et al. A helminth calicheldin-like protein suppresses antigen processing and presentation in macrophages via inhibition of lysosomal VATPase. *FASEB J.* 26, 4614–4627 (2012).
20. Steinfelder, S., O’Regan, N. L. & Hartmann, S. Diplomatic assistance: Can helminth-modulated macrophages act as treatment for inflammatory diseases? *PLoS Pathog.* 12, e1005480 (2016).
21. Britton, C., Winter, A. D., Gillan, V. & Devaney, E. micro RNAs of parasitic helminths -Identification, characterization and potential as drug targets. *Int. J. Parasitol. Drugs Drug Resist.* 4, 85–94 (2014).
22. Arora, N. et al. Micromanagement of immune system: Role of miRNAs in helminthic infections. *Front. Microbiol.* 8, 586 (2017).
23. Fromm, B. et al. The revised microRNA complement of *Fasciola hepatica* reveals a plethora of overlooked microRNAs and evidence for enrichment of immunoregulatory microRNAs in extracellular vesicles. *Int. J. Parasitol.* 45, 697–702 (2015).
24. Sámková, M. C. et al. Identification of *Schistosoma mansoni* microRNAs. *BMC Genomics* 12, 47 (2011).
25. Xu, M. J. et al. Comparative characterization of microRNAs from the liver flukes *Fasciola gigantica* and *F. hepatica*. *PLoS ONE* 7, e33387 (2012).
26. Buck, A. H. et al. Exosomes secreted by nematode parasites transfer small RNAs to mammalian cells and modulate innate immunity. *Nat. Commun.* 5, 5488 (2014).
27. Liu, J. et al. *Schistosoma japonicum* extracellular vesicle miRNA cargo regulates host macrophage functions facilitating parasitism. *PLoS Pathog.* 15, e1007817 (2019).
28. Hoy, A. M. et al. Parasite-derived microRNAs in host serum as novel biomarkers of helminth infections. *PLoS Negl. Trop. Dis.* 8, e2701 (2014).
29. Gu, H. Y. et al. Conservation of a microRNA cluster in parasitic nematodes and profiling miRNAs in excretory-secretory products and microvesicles of *Haemonchus contortus*. *PLoS Negl. Trop. Dis.* 11, e0006506 (2017).
30. Tritten, L. et al. Detection of circulating parasite- derived microRNAs in filarial infections. *PLoS Negl. Trop. Dis.* 9, e2971 (2014).
31. Fontenla, S., Dell’Oca, N., Smirich, P., Tort, J. E. & Siles-Lucas, M. The miRNome of *Fasciola hepatica* juveniles endorses the existence of a reduced set of highly divergent micro RNAs in parasitic flatworms. *Int. J. Parasitol.* 45, 901–913 (2015).
32. Cai, P., Gobert, G. N. & McManus, D. P. MicroRNAs in parasitic helminthiasis: Current status and future perspectives. *Trends Parasitol.* 32, 71–86 (2016).
33. Murphy, A. J., Guyre, P. M. & Pioi, P. A. Estrusil suppresses NF-kappa B activation through coordinated regulation of let-7a and miR-125b in primary human macrophages. *J. Immunol.* 184, 5029–5037 (2010).
34. Tili, E. et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. *J. Immunol.* 179, 5082–5089 (2007).
35. Douroux-Richard, I. et al. miR125b controls monocyte adaption to inflammation through mitochondrial metabolism and dynamics. *Blood* 132, 3125–3136 (2016).
36. Wong, N. & Wang, X. miRDR: An online resource for microRNA target prediction and functional annotations. *Nucl. Acids Res.* 43, D146-152 (2015).
We thank James Lazenby and Cynthia Whitchurch for providing *C. elegans*, Don McManus for supplying samples of *S. mansoni* RNA, and Geoff Gobert and Melissa Burke for completion of microarrays.

Author contributions
A.R. performed experiments, analyzed data and critically reviewed the manuscript; M.L. and J.T. designed and performed experiments; K.C. performed experiments and J.P.D. provided resources and critically reviewed the manuscript; T.M.M. and M.G.C. designed and executed algorithms for analysis of miRNA sequencing data; N.T. and S.D. designed and performed experiments, analyzed data and wrote the manuscript.

Funding
A.R. is a recipient of an Australian Government RTPS Scholarship. Work in M.G-C lab is supported by UIDB/04046/2020 and UIDP/04046/2020 Centre grant from FCT, Portugal (to BioISI). T.M.M. is the recipient of a fellowship from the BioSys PhD programme PD65-2012 (Ref SFRH/PD/BD/142854/2018) from FCT (Portugal). J.P.D. and K.C. are supported from Science Foundation Ireland (SFI) Professorship award 17/RP/5368.

Competing interests
The authors declare no competing interests.

Additional information

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-86125-1.

**Correspondence** and requests for materials should be addressed to S.D.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021